Enlivex Therapeutics Ltd.
ENLV
$1.09
$0.0454.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 33.31% | -98.92% | 15.96% | 25.22% | 54.48% |
| Total Depreciation and Amortization | 150.00% | -77.64% | 0.63% | -14.89% | -6.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -305.71% | -70.86% | 132.16% | 40.84% | -84.46% |
| Change in Net Operating Assets | -170.04% | 144.82% | -362.63% | 159.25% | -194.41% |
| Cash from Operations | -13.22% | -56.06% | -45.63% | 60.16% | 14.53% |
| Capital Expenditure | 8.57% | -288.89% | 43.75% | 62.79% | -514.29% |
| Sale of Property, Plant, and Equipment | 13.51% | -83.30% | 177,100.00% | -99.55% | 339.22% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.36% | 946.17% | 53.02% | -115.84% | 20.19% |
| Cash from Investing | -5.51% | 140.37% | 275.94% | -115.57% | 23.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.36% | 662.80% | -94.32% | 715.37% | 252.94% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 99.07% | -- | -- | 200.00% | 89.54% |
| Cash from Financing | -84.38% | 404.40% | -94.34% | 743.32% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -334.39% | 155.15% | -153.06% | 64.39% | 197.37% |